Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Public ClinicalTrials.gov record NCT04208958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Study identification
- NCT ID
- NCT04208958
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Drug
- VE800 Biological
- Vancomycin Oral Capsule Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2020
- Primary completion
- Aug 25, 2021
- Completion
- Feb 22, 2023
- Last update posted
- Oct 26, 2025
2020 – 2023
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| University of California Los Angeles | Los Angeles | California | 90095 | — |
| Pacific Hematology Oncology Associates | San Francisco | California | 94115 | — |
| The Angeles Clinic and Research Institute - West Los Angeles Office | Santa Monica | California | 90404 | — |
| University of California Los Angeles | Santa Monica | California | 90404 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Washington University School of Medicine Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| John Theurer Cancer Center | Hackensack | New Jersey | 07601 | — |
| New York University Medical Oncology Associates | New York | New York | 10016 | — |
| Weill Cornell Medicine | New York | New York | 10065 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| The Miriam Hospital | Providence | Rhode Island | 02906 | — |
| Baylor Scott and White Center for Advanced Heart and Lung Disese | Dallas | Texas | 75246 | — |
| Huntsman Cancer Institute and Hospital | Salt Lake City | Utah | 84112 | — |
| Swedish Medical Oncology - First Hill | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04208958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04208958 live on ClinicalTrials.gov.